Skip to main content
Diabetes Care logoLink to Diabetes Care
. 2019 Apr 1;42(6):1155. doi: 10.2337/dc19-er06a

Erratum. Urine Complement Proteins and the Risk of Kidney Disease Progression and Mortality in Type 2 Diabetes. Diabetes Care 2018;41:2361–2369

Tomas Vaisar, Blythe Durbin-Johnson, Kathryn Whitlock, Ilona Babenko, Rajnish Mehrotra, David M Rocke, Maryam Afkarian
PMCID: PMC6609947  PMID: 30936112

In the article cited above, the authors miscategorized CD59 as a transmembrane protein when it is in fact a glycosylphosphatidylinositol-anchored surface protein. The sentence on page 2367 in the last paragraph of the first column was corrected to read: CD59, a major regulator of the complement activity, is a glycosylphosphatidylinositol-anchored membrane protein that binds to the C5–8 complex and inhibits assembly of C9 monomers into the terminal complement complex, thus protecting cells from complement-mediated injury (33).

The error does not change the results or conclusions of the article.

The online version of the article has been corrected to reflect these changes.


Articles from Diabetes Care are provided here courtesy of American Diabetes Association

RESOURCES